CVS has restored a obesity medication developed by Eli Lilly to its covered drug formularies, according to a pharmaceutical industry briefing published by STAT News on May 28, 2026.
Formulary Reinstatement
Formulary decisions by major pharmacy benefit managers carry significant weight for patient access and drug pricing dynamics. When a large insurer or pharmacy network removes a medication from its covered list, patients may face substantially higher out-of-pocket costs or be required to switch to alternative treatments. Reinstatement reverses that dynamic, potentially broadening access for individuals whose plans are administered through CVS.
The STAT News briefing did not provide additional detail on the timeline of the original removal or the terms under which the Lilly obesity drug was returned to the formulary. The report was part of a broader morning roundup of pharmaceutical industry developments.
Hepatitis B Drug Also Covered
The same briefing included coverage of a hepatitis B drug, though specific details about the compound, its developer, or its regulatory or commercial status were not elaborated upon in the available reporting. Hepatitis B remains a significant global health concern, and drug development in that space has seen renewed activity in recent years as researchers pursue functional cure strategies alongside existing antiviral maintenance therapies.
Context on Obesity Drug Coverage
The obesity drug category has become one of the most closely watched segments in the pharmaceutical industry, driven largely by the commercial success of glucagon-like peptide-1 receptor agonists. Formulary decisions around these medications have been a recurring point of tension between drugmakers, insurers, and pharmacy benefit managers, with coverage determinations frequently shifting in response to pricing negotiations and clinical evidence reviews.
CVS's decision to return the Lilly product to its formularies adds another data point to an ongoing pattern of coverage fluctuation in this therapeutic area. The full implications for patient access will depend on the specific plan types affected and the terms of any updated pricing arrangements.
Further details from the STAT News Pharmalittle briefing were available to subscribers of the publication's STAT+ service.